Brief: Can-Fite Positive New Data From It's Phase III Psoriasis Study Will Be Presented At An Industry Expert Summit
02/11/2022 11:36
Nov 2 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE: POSITIVE NEW DATA FROM IT’S PHASE III PSORIASIS
STUDY
WILL BE PRESENTED TODAY AT AN INDUSTRY EXPERT SUMMIT IN BOSTON
Source text for Eikon: ID:nBw3m1v7ma
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage